"Janus Kinase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is involved in signaling from a broad variety of CYTOKINE RECEPTORS.
| Descriptor ID |
D053613
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124.100 D12.776.476.393.100
|
| Concept/Terms |
Janus Kinase 1- Janus Kinase 1
- JAK-1 Protein Tyrosine Kinase
- JAK 1 Protein Tyrosine Kinase
- JAK1 Protein Tyrosine Kinase
- Jak1 Kinase
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase 1".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 1".
This graph shows the total number of publications written about "Janus Kinase 1" by people in this website by year, and whether "Janus Kinase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 2 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 2 | 3 |
| 2011 | 4 | 3 | 7 |
| 2012 | 1 | 5 | 6 |
| 2013 | 2 | 1 | 3 |
| 2014 | 2 | 2 | 4 |
| 2015 | 3 | 0 | 3 |
| 2016 | 5 | 1 | 6 |
| 2017 | 3 | 4 | 7 |
| 2018 | 0 | 3 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 3 | 3 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase 1" by people in Profiles.
-
Individuals with JAK1 variants are affected by syndromic features encompassing autoimmunity, atopy, colitis, and dermatitis. J Exp Med. 2024 Jun 03; 221(6).
-
Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study. Br J Haematol. 2022 09; 198(6):1065-1068.
-
B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy. J Immunother. 2022 05 01; 45(4):187-193.
-
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. Br J Haematol. 2022 07; 198(2):317-327.
-
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol. 2021 Apr; 17(12):1449-1458.
-
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020 09 22; 4(18):4282-4291.
-
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019 07 15; 129(8):3324-3338.
-
New Concepts of Treatment for Patients with Myelofibrosis. Curr Treat Options Oncol. 2019 01 24; 20(1):5.
-
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res. 2018 10; 73:78-85.
-
Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. Cancer Med. 2018 11; 7(11):5382-5393.